World-leading cancer researchers announce plans to create a new generation of treatments that target the ecosystems supporting cancer. Their new strategy sees cancer genetics and evolution within complex ecosystems as keys to creating new targeted drugs and immunotherapies. They aim to double survival for people with advanced cancer within a decade by combining existing treatments and using smart dosing strategies

Personalised cancer medicine start-up Curesponse has become the latest MedTech company to move in at the Innovation Gateway at The London Cancer Hub in Sutton, south London.

Members of the ICR’s Discovery Club gathered at The Royal Society to hear about our new five-year research strategy and to mark two years since the opening of our pioneering Centre for Cancer Drug Discovery.